Quality of life and patient-perceived difficulties in the treatment of type 2 diabetes
- PMID: 22972444
- PMCID: PMC3448173
- DOI: 10.1900/RDS.2012.9.46
Quality of life and patient-perceived difficulties in the treatment of type 2 diabetes
Abstract
Background: Clinical evidence points to patient-perceived difficulties and compliance problems in implementing early insulin therapy. Therefore, individual treatment aims are necessary to optimize diabetes therapy, as currently acknowledged by the new ADA/EASD guidelines. Better characterization of patient-perceived difficulties in the implementation of early insulin treatment may contribute to improved compliance and optimal tailoring of treatment regimens for the individual patient.
Objectives: To assess differences in quality of life (QoL) and patient-perceived difficulties in health care with every addition of oral hypoglycemic agents (OHAs) and insulin therapy.
Methods: The analysis was conducted on a cross-sectional sample of 714 diabetic patients treated with OHAs or with insulin once or twice daily. Differences in diabetes-specific QoL, overall QoL, and perception of difficulties associated with specific diabetes treatment attributes were evaluated using trend analysis and comparisons between groups. The contribution of each diabetes treatment attribute to QoL measures and glycemic control was also assessed.
Results: No significant differences were found in QoL measures among patients treated exclusively with OHAs when these patients were assessed by the number of oral agents, irrespective of the degree of glycemic control. Better controlled patients treated with 2 OHAs, compared with poorly controlled patients treated with a single OHA, had a lower perception of difficulties associated with diabetes treatment attributes. Poorly controlled patients treated with 2 OHAs and better controlled patients treated with 3 OHAs had similar QoL and perceived difficulties with care. However, the insulin-based alternative was consistently associated with a significantly higher perception of pain and lower overall QoL when compared with the oral regimens. Multivariate models accounted for 52% and 32% of the variance in QoL measures.
Conclusions: From the patients' perspective, oral therapy is the preferred strategy for attaining the treatment goals since the addition of OHAs was not associated with lower QoL or patient-perceived difficulties with care. If early insulin treatment is considered, physicians should address specific diabetes treatment characteristics, mainly the issue of pain, to promote improved QoL and disease control.
Similar articles
-
Evaluation of perception of insulin therapy among Chinese patients with type 2 diabetes mellitus.Diabetes Metab. 2011 Nov;37(5):389-94. doi: 10.1016/j.diabet.2010.12.008. Epub 2011 Mar 31. Diabetes Metab. 2011. PMID: 21458350
-
Characteristics Predictive for a Successful Switch from Insulin Analogue Therapy to Oral Hypoglycemic Agents in Patients with Type 2 Diabetes.Yonsei Med J. 2016 Nov;57(6):1395-403. doi: 10.3349/ymj.2016.57.6.1395. Yonsei Med J. 2016. PMID: 27593867 Free PMC article.
-
Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient- and physician-related factors): A prospective observational DIPP-FACTOR study in Korea.J Diabetes Investig. 2017 May;8(3):346-353. doi: 10.1111/jdi.12581. Epub 2017 Mar 30. J Diabetes Investig. 2017. PMID: 27712034 Free PMC article.
-
Effects on All-cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-analysis of Randomized Controlled Trials.Clin Ther. 2016 Feb;38(2):372-386.e6. doi: 10.1016/j.clinthera.2015.12.006. Epub 2016 Jan 7. Clin Ther. 2016. PMID: 26774276 Review.
-
Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.Diabetes Obes Metab. 2008 Jul;10 Suppl 2:50-65. doi: 10.1111/j.1463-1326.2008.00871.x. Diabetes Obes Metab. 2008. PMID: 18577157 Review.
Cited by
-
Association Between Pharmacological Treatment Regimens and Quality of Life Among Rural Type 2 Diabetic Patients: A Comparative Analysis in Eastern China.Inquiry. 2024 Jan-Dec;61:469580241288683. doi: 10.1177/00469580241288683. Inquiry. 2024. PMID: 39415363 Free PMC article.
-
Insulin Therapy in Type 2 Diabetes Is Associated With Barriers to Activity and Worse Health Status: A Cross-Sectional Study in Primary Care.Front Endocrinol (Lausanne). 2021 Mar 10;12:573235. doi: 10.3389/fendo.2021.573235. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33776906 Free PMC article.
-
Comparing assessment of diabetes-related quality of life between patients and their physicians.Health Qual Life Outcomes. 2018 Nov 19;16(1):214. doi: 10.1186/s12955-018-1040-6. Health Qual Life Outcomes. 2018. PMID: 30453978 Free PMC article.
-
Insulin therapy in type 2 diabetes: Insights into clinical efficacy, patient-reported outcomes, and adherence challenges.World J Diabetes. 2024 May 15;15(5):828-852. doi: 10.4239/wjd.v15.i5.828. World J Diabetes. 2024. PMID: 38766443 Free PMC article. Review.
-
Relationship of treatment satisfaction to health-related quality of life among Palestinian patients with type 2 diabetes mellitus: Findings from a cross-sectional study.J Clin Transl Endocrinol. 2015 Mar 31;2(2):66-71. doi: 10.1016/j.jcte.2015.03.002. eCollection 2015 Jun. J Clin Transl Endocrinol. 2015. PMID: 29159112 Free PMC article.
References
-
- Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev. 1999;15:205–218. - PubMed
-
- Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203. - PMC - PubMed
-
- LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med. 2002;113(Suppl 6A):3S–11S. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials